GSA Capital Partners LLP Grows Stake in Altimmune, Inc. (NASDAQ:ALT)

GSA Capital Partners LLP raised its stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 153.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 445,868 shares of the company's stock after purchasing an additional 269,676 shares during the quarter. GSA Capital Partners LLP owned about 0.83% of Altimmune worth $1,159,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. MML Investors Services LLC grew its stake in shares of Altimmune by 10.7% during the first quarter. MML Investors Services LLC now owns 22,140 shares of the company's stock valued at $93,000 after acquiring an additional 2,135 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Altimmune by 18.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 20,396 shares of the company's stock valued at $86,000 after acquiring an additional 3,122 shares in the last quarter. Credit Suisse AG grew its stake in shares of Altimmune by 8.5% during the first quarter. Credit Suisse AG now owns 41,372 shares of the company's stock valued at $175,000 after acquiring an additional 3,235 shares in the last quarter. Osaic Holdings Inc. grew its stake in shares of Altimmune by 77.3% during the second quarter. Osaic Holdings Inc. now owns 7,834 shares of the company's stock valued at $28,000 after acquiring an additional 3,416 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Altimmune by 2.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 177,865 shares of the company's stock valued at $2,925,000 after acquiring an additional 3,492 shares in the last quarter. 66.99% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on ALT shares. The Goldman Sachs Group started coverage on Altimmune in a research note on Wednesday, January 24th. They set a "neutral" rating and a $13.00 target price for the company. B. Riley restated a "buy" rating and set a $20.00 target price on shares of Altimmune in a research note on Tuesday, February 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Altimmune in a research note on Friday, December 1st.

Altimmune Trading Up 3.6 %

NASDAQ:ALT opened at $10.39 on Friday. Altimmune, Inc. has a one year low of $2.09 and a one year high of $14.84. The stock has a 50-day simple moving average of $10.39 and a 200 day simple moving average of $6.06.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.

Want to see what other hedge funds are holding ALT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Altimmune, Inc. (NASDAQ:ALT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.